Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis. Issue 15 (April 2020)

• Record Type: Journal Article
• Authors: Feng, Ziqiao; Zhang, Yunqiao; You, Xu; Zhang, Wenyu; Ma, Yuhan; Long, Qing; Liu, Zijun; Hao, Wei; Zeng, Yong; Teng, Zhaowei
• Other Names: Pantic. Igor V. section editor.
• Is Part Of: Medicine. Volume 99:Issue 15(2020)
• Publication Date: 2020-04
• Subjects: interleukin-6 -- meta-analysis -- risperidone -- schizophrenia; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000019694
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: To evaluate the association between risperidone use and interleukin-6 (IL-6) levels by conducting a meta-analysis of controlled before-and-after studies. Methods: Studies were identified through a systematic search of PubMed and Embase. The mean and standardized differences were extracted to calculate the standardized mean differences. IL-6 levels were compared in patients with schizophrenia before and after risperidone treatment. Results: Ten studies were included in the final meta-analysis. The primary findings from our study suggest that there was a significant decrease in serum IL-6 levels after risperidone treatment ( P = .021). A subgroup analysis revealed the sources of heterogeneity. The sensitivity analysis indicated that the results were stable, and no publication bias was observed. Conclusions: The present meta-analysis provides evidence that risperidone can significantly reduce IL-6 levels in schizophrenia. IL-6 is a potential biomarker of the pathophysiology and clinical processes of schizophrenia.